tradingview
Liminatus Pharma Disclosed Failure to Satisfy a Continued Listing Rule or Standard
On July 20, 2026, Nasdaq notified the company that it has not regained compliance with Nasdaq Listing Rule 5450(a)(1) (the $1.00 minimum bid price) and is not eligible for a second 180-day extension. The matter is before the Nasdaq Hearings Panel, and the company must submit its written response by…